TG Therapeutics Inc [TGTX] stock is trading at $18.40, up 0.49%. An important factor to consider is whether the stock is rising or falling in short-term value. The TGTX shares have gain 3.78% over the last week, with a monthly amount glided 12.68%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
TG Therapeutics Inc [NASDAQ: TGTX] stock has seen the most recent analyst activity on August 02, 2023, when Goldman upgraded its rating to a Neutral and also revised its price target to $12 from $16. On May 20, 2022, BofA Securities initiated with a Underperform rating and assigned a price target of $5 on the stock. B. Riley Securities reiterated its Buy rating and decreased its price target to $35 on February 23, 2022. Goldman downgraded its rating to a Sell and reduced its price target to $26 on November 15, 2021. Goldman started tracking with a Neutral rating for this stock on April 20, 2021, and assigned it a price target of $50. In a note dated April 19, 2021, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $79 to $89.
TG Therapeutics Inc [TGTX] stock has fluctuated between $6.46 and $26.95 over the past year. Currently, Wall Street analysts expect the stock to reach $23.4 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $18.40 at the most recent close of the market. An investor can expect a potential return of 27.17% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
TG Therapeutics Inc [NASDAQ:TGTX] reported sales of 289.33M for the trailing twelve months, which represents a growth of 713.46%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is -0.06 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.64.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.29 points at the first support level, and at 17.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.19, and for the 2nd resistance point, it is at 19.60.
Ratios To Look Out For
For context, TG Therapeutics Inc’s Current Ratio is 3.62. On the other hand, the Quick Ratio is 2.84, and the Cash Ratio is 0.76. Considering the valuation of this stock, the price to sales ratio is 9.83, the price to book ratio is 17.76 and price to earnings (TTM) ratio is 83.45.
Transactions by insiders
Recent insider trading involved Lonial Sagar, Director, that happened on Jun 20 ’24 when 16348.0 shares were sold. Director, Lonial Sagar completed a deal on Jun 17 ’24 to sell 9585.0 shares. Meanwhile, Director Lonial Sagar sold 5000.0 shares on Mar 13 ’24.
